Merck Q2 2025 presentation: KEYTRUDA growth offsets GARDASIL decline in China
PositiveFinancial Markets

In its Q2 2025 presentation, Merck reported that the growth of its cancer drug KEYTRUDA has successfully offset the decline in sales of GARDASIL in China. This is significant as it highlights Merck's ability to adapt and thrive in challenging markets, ensuring continued revenue streams despite fluctuations in product performance. The strong performance of KEYTRUDA not only reinforces Merck's position in the oncology sector but also showcases the company's resilience and strategic focus on high-demand therapies.
— Curated by the World Pulse Now AI Editorial System